These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 16184031

  • 21. Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.
    Patel M, Sheng Y, Mandava NK, Pal D, Mitra AK.
    Int J Pharm; 2014 Dec 10; 476(1-2):99-107. PubMed ID: 25261710
    [Abstract] [Full Text] [Related]

  • 22. ABCB1 1199G>A Polymorphism Affects the Intracellular Accumulation of Antidepressants in LLC-PK1 Recombinant Cell Lines.
    Gao YL, He B.
    DNA Cell Biol; 2018 Dec 10; 37(12):1055-1060. PubMed ID: 30256659
    [Abstract] [Full Text] [Related]

  • 23. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer.
    Fung KL, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.
    Cancer Res; 2014 Jan 15; 74(2):598-608. PubMed ID: 24305879
    [Abstract] [Full Text] [Related]

  • 24. Effects of MDR1 (C3435T) Polymorphism on Resistance, Uptake, and Efflux to Antiepileptic Drugs.
    Shen XM, Cheng J.
    DNA Cell Biol; 2019 Mar 15; 38(3):250-255. PubMed ID: 30632789
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
    Karyekar CS, Eddington ND, Garimella TS, Gubbins PO, Dowling TC.
    Pharmacotherapy; 2003 Apr 15; 23(4):436-42. PubMed ID: 12680473
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
    Jain R, Agarwal S, Majumdar S, Zhu X, Pal D, Mitra AK.
    Int J Pharm; 2005 Oct 13; 303(1-2):8-19. PubMed ID: 16137847
    [Abstract] [Full Text] [Related]

  • 29. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.
    Antivir Ther; 2001 Dec 13; 6(4):201-29. PubMed ID: 11878403
    [Abstract] [Full Text] [Related]

  • 30. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
    Patel J, Hussain A, Pal D, Mitra AK.
    Am J Ther; 2004 Dec 13; 11(2):114-23. PubMed ID: 14999363
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery.
    Luo S, Kansara VS, Zhu X, Mandava NK, Pal D, Mitra AK.
    Mol Pharm; 2006 Dec 13; 3(3):329-39. PubMed ID: 16749865
    [Abstract] [Full Text] [Related]

  • 33. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.
    Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS.
    Mol Pharmacol; 1999 Aug 13; 56(2):383-9. PubMed ID: 10419558
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
    Gupta A, Zhang Y, Unadkat JD, Mao Q.
    J Pharmacol Exp Ther; 2004 Jul 13; 310(1):334-41. PubMed ID: 15007102
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
    Richter M, Gyémánt N, Molnár J, Hilgeroth A.
    Pharm Res; 2004 Oct 13; 21(10):1862-6. PubMed ID: 15553233
    [Abstract] [Full Text] [Related]

  • 38. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
    Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH.
    Mol Pharmacol; 2001 Apr 13; 59(4):806-13. PubMed ID: 11259625
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells.
    Crouthamel MH, Wu D, Yang Z, Ho RJ.
    J Pharm Sci; 2006 Dec 13; 95(12):2767-77. PubMed ID: 16917872
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.